All News

2019

June

Media Release / Jun 14, 2019

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)

Read More
Media Release / Jun 04, 2019

Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®

Read More
Media Release / Jun 03, 2019

Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Read More

May

Media Release / May 24, 2019

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Read More
Media Release / May 24, 2019

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

Read More
Media Release / May 24, 2019

AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Read More

April

Media Release / Apr 24, 2019

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Read More
Trees casting shadows along Fabrikstrasse
Featured News / Apr 24, 2019

Novartis Financial Results – Q1 2019

Novartis announced the company’s financial results for the first quarter of 2019.

Read More
Media Release / Apr 15, 2019

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Read More
Media Release / Apr 15, 2019

Europe-Africa partnership spearheads development of next-generation antimalarial drug

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More